premargin

Element List	Explanation
Announcement Detail	Qomel Company announces that the Board of Directors, in its meeting held on 20/04/1447H corresponding to 12/10/2025G, resolved to approve an investment in Kure Cells, a U.S. company operating in biotechnology, cell therapies, and regenerative medicine. The investment totals approximately USD 1,382,000 (equivalent to SAR 5,182,500 at an exchange rate of SAR 3.75 per USD). The share price is USD 94, and the estimated post-closing ownership will be around 1.3% (a non-controlling stake). The Company will fund the investment from its own internal resources. This investment aligns with Qomel’s strategic direction to invest in the development of advanced therapeutic products and technologies with growing demand and promising market prospects and is consistent with the Company’s overall strategy. It is worth noting that Kure Cells is a U.S. company (incorporated under Delaware law following a re-incorporation). It is a leading biotechnology company focused on developing cell-based therapy technologies within regenerative medicine, with an emphasis on rapid-manufacturing platforms for CAR-T therapies and research-stage oncology programs. Expected financial impact: No immediate material impact is anticipated; any future impact—if any—will depend on the performance of the target company and the development of Qomel’s investment therein. Qomel will disclose any material developments in this regard as they arise. The Company also confirms that there are no related parties involved in this investment.

Element List

Explanation

Announcement Detail

Qomel Company announces that the Board of Directors, in its meeting held on 20/04/1447H corresponding to 12/10/2025G, resolved to approve an investment in Kure Cells, a U.S. company operating in biotechnology, cell therapies, and regenerative medicine. The investment totals approximately USD 1,382,000 (equivalent to SAR 5,182,500 at an exchange rate of SAR 3.75 per USD). The share price is USD 94, and the estimated post-closing ownership will be around 1.3% (a non-controlling stake). The Company will fund the investment from its own internal resources.

This investment aligns with Qomel’s strategic direction to invest in the development of advanced therapeutic products and technologies with growing demand and promising market prospects and is consistent with the Company’s overall strategy.

It is worth noting that Kure Cells is a U.S. company (incorporated under Delaware law following a re-incorporation). It is a leading biotechnology company focused on developing cell-based therapy technologies within regenerative medicine, with an emphasis on rapid-manufacturing platforms for CAR-T therapies and research-stage oncology programs.

Expected financial impact: No immediate material impact is anticipated; any future impact—if any—will depend on the performance of the target company and the development of Qomel’s investment therein. Qomel will disclose any material developments in this regard as they arise.

The Company also confirms that there are no related parties involved in this investment.

Qomel Company announces that its Board of Directors has approved an investment in Kure Cells, a U.S.-based company